Governance

Governance

Since November 2018, the Coordinator of ERN eUROGEN is Prof Wout Feitz, Paediatric Urological Surgeon at Radboudumc, NL, supported by three workstream leaders:

  • Workstream 1 – Rare congential uro-rectal genital anomalies: Prof Wout Feitz, Paediatric Urological Surgeon, Radboudumc, NL
  • Workstream 2 – Complex urogenital conditions requiring highly specialised surgery: Prof Margit Fisch, Urological Surgeon, Universitätsklinikum Hamburg-Eppendorf, DE
  • Workstream 3 – Rare urogenital cancers: Prof Vijay Sangar, Urological Surgeon, The Christie NHS Foundation Trust, UK

Strategic Board
The Strategic Board for ERN eUROGEN is chaired by the Coordinator and includes one representative from each healthcare provider, a representative from the patient advisory board, a representative from the European Association of Urology and a representative of the European Commission. Members of the Board may appoint a Deputy if they are not able to attend a Board meeting. Decisions will be taken by consensus or a majority agreement of 80%. The Strategic Board will be responsible for discussing strategic issues relating to the development and expansion of the activities of the ERN, such as new applications from HCPs and Affiliated Partners and initiatives relating to guideline development, dissemination of information and training.

Operational Board
The Operational Board is comprised of the Coordinator, the Manager, the three workstream leaders, a representative of the EAU Guidelines Office, and a representative of the patient advisory group. An ex officio position will be available to a representative of the European Commission. Where added value can be achieved, other ERN networks will be invited to be represented. The Operational Board will report and make recommendations to the Strategic Board for ERN eUROGEN.

The Operational Board will meet at regular intervals using the IT platform, and as much as possible will develop standard operating procedures, initiate new education and (surgical) training activities and stimulate and initiate research developments within the fields of expertise and patients interest. Actions will be set for new specific guideline development. The workstream structure and patient and expertise input will be used to uniform approaches in all Member States. The Operational Board will meet more frequently (3 times a year) than the Strategic Board (once a year). Workstream leaders will hold meetings via the IT platform according to need, but at least 3 times a year.

Advisory Boards
Advisory Boards will deliver input from other fields of expertise as well as from the involved patient organisations. Evaluation and audit systems will be developed for quality control and improvement of the whole network and specific healthcare where needed.